Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD. Participants will be asked to: * Take tirzepatide for 12 months. * Come in for clinic visits every 3 months. * Have blood drawn at baseline, 6, and 12 months. * Complete a liver ultrasound at baseline and at 12 months.

NCT Number	NCT06934642
Lead Sponsor	University of New Mexico Collaborators: American Cancer Society, Inc., University of New Mexico Cancer Center
Conditions	MASLD, Obesity
Enrollment	8 participants
Start Date	2025-06-30
Primary Completion	2026-08 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-15